Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
